Literature DB >> 30247227

Prevalence of Seizures in Pediatric Extracorporeal Membrane Oxygenation Patients as Measured by Continuous Electroencephalography.

Shunpei Okochi1, Aqsa Shakoor1, Sunjay Barton2, Ariela R Zenilman1, Cherease Street1, Svetlana Streltsova3, Eva W Cheung4, William Middlesworth1, Jennifer M Bain5.   

Abstract

OBJECTIVES: Standards for neuromonitoring during extracorporeal membrane oxygenation support do not currently exist, and there is wide variability in practice. We present our institutional experience at an academic children's hospital since establishment of a continuous electroencephalography monitoring protocol for extracorporeal membrane oxygenation patients.
DESIGN: Retrospective, single-center study.
SETTING: Neonatal ICU and PICU in an urban, quaternary care center. PATIENTS: All neonatal and pediatric patients requiring extracorporeal membrane oxygenation.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: During the study period, 70 patients were cannulated for extracorporeal membrane oxygenation and had continuous electroencephalography monitoring for greater than 24 hours. Electroencephalographic seizures were observed in 16 of 70 patients (23%), including five patients (7%) who were in status epilepticus. Among patients with continuous electroencephalography seizures, nine (56%) had subclinical nonconvulsive status epilepticus and eight (50%) had seizures in the initial 24 hours of extracorporeal membrane oxygenation support. Survival to hospital discharge was significantly greater for extracorporeal membrane oxygenation patients without seizures (74% vs 44%; p = 0.02).
CONCLUSIONS: Seizures occur in a significant proportion of pediatric and neonatal extracorporeal membrane oxygenation patients, frequently in the initial 24 hours after extracorporeal membrane oxygenation cannulation. Because seizures are associated with significantly decreased survival, neuromonitoring early in the extracorporeal membrane oxygenation course is important and useful. Further studies are needed to correlate electroencephalography findings with neurologic outcome.

Entities:  

Mesh:

Year:  2018        PMID: 30247227     DOI: 10.1097/PCC.0000000000001730

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  6 in total

1.  Clinical and Hematological Outcomes of Aminocaproic Acid Use During Pediatric Cardiac ECMO.

Authors:  Madison Coleman; Joel Davis; Kevin O Maher; Shriprasad R Deshpande
Journal:  J Extra Corpor Technol       Date:  2021-03

Review 2.  Multimodal Neurologic Monitoring in Children With Acute Brain Injury.

Authors:  Jennifer C Laws; Lori C Jordan; Lindsay M Pagano; John C Wellons; Michael S Wolf
Journal:  Pediatr Neurol       Date:  2022-02-02       Impact factor: 3.372

Review 3.  Neurological Monitoring and Complications of Pediatric Extracorporeal Membrane Oxygenation Support.

Authors:  Ahmed S Said; Kristin P Guilliams; Melania M Bembea
Journal:  Pediatr Neurol       Date:  2020-03-19       Impact factor: 3.372

4.  Characteristics of Neonates with Cardiopulmonary Disease Who Experience Seizures: A Multicenter Study.

Authors:  Shavonne L Massey; Hannah C Glass; Renée A Shellhaas; Sonia Bonifacio; Taeun Chang; Catherine Chu; Maria Roberta Cilio; Monica E Lemmon; Charles E McCulloch; Janet S Soul; Cameron Thomas; Courtney J Wusthoff; Rui Xiao; Nicholas S Abend
Journal:  J Pediatr       Date:  2021-10-30       Impact factor: 4.406

5.  Seizures in children undergoing extracorporeal membrane oxygenation: a systematic review and meta-analysis.

Authors:  Guisen Lin; Yaowen Li; Yijiang Zhuang; Qimeng Fan; Yi Luo; Hongwu Zeng
Journal:  Pediatr Res       Date:  2022-07-29       Impact factor: 3.953

6.  Population Pharmacokinetics of Phenobarbital in Neonates and Infants on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.

Authors:  Céline Thibault; Shavonne L Massey; Nicholas S Abend; Maryam Y Naim; Alexandra Zoraian; Athena F Zuppa
Journal:  J Clin Pharmacol       Date:  2020-09-22       Impact factor: 3.126

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.